Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TIDAL-01 by Turnstone Biologics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
TIDAL-01 is under clinical development by Turnstone Biologics and currently in Phase I for Recurrent Head And Neck Squamous Cell...
Risk adjusted net present value: What is the current valuation of Turnstone Biologics's TIDAL-01?
TIDAL-01 is a cell therapy commercialized by Turnstone Biologics, with a leading Phase I program in Solid Tumor;Metastatic Uveal Melanoma....
Risk adjusted net present value: What is the current valuation of Turnstone Biologics's TIDAL-01?
TIDAL-01 is a cell therapy commercialized by Turnstone Biologics, with a leading Phase I program in Human Epidermal Growth Factor...